Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Rigel Pharmaceuticals stock in Canada | $3.72

Own Rigel Pharmaceuticals shares in just a few minutes.

Rigel Pharmaceuticals, Inc
-$0.06 (-1.44%)

Rigel Pharmaceuticals is a biotechnology business based in the US. Rigel Pharmaceuticals stocks (RIGL.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.19 – an increase of 4.2% over the previous week. Rigel Pharmaceuticals employs 169 staff and has a trailing 12-month revenue of around $133.9 million.

How to buy Rigel Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: RIGL in this case.
  5. Research Rigel Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your Rigel Pharmaceuticals stocks. It's that simple.

How has Coronavirus impacted Rigel Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Rigel Pharmaceuticals's stock price has had significant positive movement.

Its last market close was $3.72, which is 38.17% up on its pre-crash value of $2.3 and 202.44% up on the lowest point reached during the March crash when the stocks fell as low as $1.23.

If you had bought $1,000 worth of Rigel Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $612.43 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,593.16.

Rigel Pharmaceuticals stock price

Use our graph to track the performance of RIGL stocks over time.

Rigel Pharmaceuticals stocks at a glance

Information last updated 2021-07-23.
Latest market close$3.72
52-week range$2.14 - $5.5
50-day moving average $4.2132
200-day moving average $3.9024
Wall St. target price$8.5
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.352

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Rigel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Rigel Pharmaceuticals price performance over time

Historical closes compared with the last close of $3.72

1 month (2021-06-25) -18.06%
3 months (2021-04-26) -4.62%

Rigel Pharmaceuticals financials

Revenue TTM USD$133.9 million
Gross profit TTM USD$47.6 million
Return on assets TTM -2.87%
Return on equity TTM -14.65%
Profit margin -8.58%
Book value $0.46
Market capitalisation USD$711.3 million

TTM: trailing 12 months

How to short and sell Rigel Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "RIGL.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 21.6 million Rigel Pharmaceuticals stocks held short by investors – that's known as Rigel Pharmaceuticals's "short interest". This figure is 11% down from 24.3 million last month.

There are a few different ways that this level of interest in shorting Rigel Pharmaceuticals stocks can be evaluated.

Rigel Pharmaceuticals's "short interest ratio" (SIR)

Rigel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rigel Pharmaceuticals stocks currently shorted divided by the average quantity of Rigel Pharmaceuticals stocks traded daily (recently around 2.3 million). Rigel Pharmaceuticals's SIR currently stands at 9.47. In other words for every 100,000 Rigel Pharmaceuticals stocks traded daily on the market, roughly 9470 stocks are currently held short.

However Rigel Pharmaceuticals's short interest can also be evaluated against the total number of Rigel Pharmaceuticals stocks, or, against the total number of tradable Rigel Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rigel Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding stocks (for every 100,000 Rigel Pharmaceuticals stocks in existence, roughly 130 stocks are currently held short) or 0.1273% of the tradable stocks (for every 100,000 tradable Rigel Pharmaceuticals stocks, roughly 127 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Rigel Pharmaceuticals.

Find out more about how you can short Rigel Pharmaceuticals stock.

Rigel Pharmaceuticals stock dividends

We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have Rigel Pharmaceuticals stocks ever split?

Rigel Pharmaceuticals stocks were split on a 1:9 basis on 25 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals stocks – just the quantity. However, indirectly, the new 800% higher stock price could have impacted the market appetite for Rigel Pharmaceuticals stocks which in turn could have impacted Rigel Pharmaceuticals's stock price.

Rigel Pharmaceuticals stock price volatility

Over the last 12 months, Rigel Pharmaceuticals's stocks have ranged in value from as little as $2.14 up to $5.5. A popular way to gauge a stock's volatility is its "beta".

RIGL.US volatility(beta: 1.51)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.506. This would suggest that Rigel Pharmaceuticals's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Rigel Pharmaceuticals overview

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Stocks similar to Rigel Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site